A--Data Coordinating Center (DCC) for the Best Pharmaceuticals for Children Act (B
ID: 75N94025R00006Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NICHDBETHESDA, MD, 20817, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/69932d100f654ffb96470b7b437edeb9/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute of Child Health and Human Development (NICHD), is seeking qualified small businesses to support the Data Coordinating Center (DCC) for the Best Pharmaceuticals for Children Act (BPCA). The primary objective of this procurement is to provide comprehensive data management, analysis, and regulatory reporting services for pediatric clinical trials, ensuring compliance with FDA regulations and facilitating data submission to the FDA and the NICHD Data Repository. This initiative is crucial for enhancing pediatric health outcomes by addressing therapeutic gaps and conducting necessary clinical studies, as mandated by the reauthorized BPCA. Interested parties must submit their capability statements by January 28, 2025, and can contact Deborah Brock at Deborah.Brock@nih.gov for further information.

    Point(s) of Contact
    BROCK, DEBORAH S
    Deborah.Brock@nih.gov
    Files
    Title
    Posted
    BPCA_DCC_SBSS_1_13_2025_1.doc
    The Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center (DCC) is seeking qualified small businesses to assist in pediatric drug development, focusing on improving the safety and effectiveness of medications for children. This sources sought announcement outlines the government’s need for agencies to provide data management, analysis, and regulatory reporting for pediatric clinical trials. The BPCA, reauthorized in 2022, mandates the NIH, through NICHD, to identify therapeutic gaps and conduct necessary clinical studies. The DCC will manage data for ongoing and new trials, ensuring compliance with FDA regulations and facilitating data submission to both the FDA and the NICHD Data Repository. Notable responsibilities include developing data management systems, providing regulatory oversight, and ensuring high quality and integrity in data collection for trials. Interested small businesses must demonstrate experience in managing pediatric clinical trials and compliance with data security protocols. The deadline for submissions of capability statements is January 28, 2025. This initiative aligns with federal goals to enhance pediatric health outcomes through collaborative research and regulatory support.
    Lifecycle
    Title
    Type
    A--Data Coordinating Center (DCC) for the Best Pharmaceuticals for Children Act (B
    Currently viewing
    Sources Sought
    Similar Opportunities
    CIVICs Data Management and Coordinating Center (DMCC)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide services for the renewal of the CIVICs Data Management and Coordinating Center (DMCC). The DMCC will support the CIVICs program by managing data, conducting analyses, and facilitating communication and coordination among various stakeholders, with a focus on advancing influenza vaccine research and development. This initiative is critical for enhancing the immunogenicity and durability of seasonal influenza vaccines and involves the operation of a scalable data management system, maintenance of public and private portals, and comprehensive program coordination. Interested parties must submit their tailored Capability Statements by 3:00 PM (Eastern Time) on January 23, 2025, to Maribel Miranda at maribel.miranda@nih.gov, with the anticipated contract award date around July 2026.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases
    Health And Human Services, Department Of
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking industry partners for clinical research collaborations focused on therapeutics, diagnostics, or devices for childhood cholestatic liver diseases. The initiative aims to engage collaborators in providing novel therapeutic agents and diagnostic tools for use in NIH-sponsored multi-center clinical trials targeting conditions such as biliary atresia and alpha-one antitrypsin deficiency, among others. This collaboration is critical for advancing research and improving clinical outcomes for children suffering from these rare liver diseases. Interested organizations must submit a Capability Statement detailing their proposed solutions and capabilities, with no funding provided by NIDDK for this opportunity. For inquiries, contact Edward Doo at dooe@niddk.nih.gov or Katrina Loh at katrina.loh@nih.gov.
    SOURCES SOUGHT: Neurodegenerative Disease Scientific Data Analysis and Consulting Services
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small business sources for scientific data analysis and consulting services related to neurodegenerative diseases, particularly Alzheimer’s disease and related dementias. The objective of this procurement is to obtain advanced analytics support to integrate and analyze complex datasets, including imaging, genomic, and clinical data, to identify disease mechanisms and therapeutic targets. This initiative is crucial for enhancing research capabilities and ensuring data accessibility and interoperability within the scientific community. Interested parties must submit their capability statements by January 24, 2025, to Hashim Dasti at hashim.dasti@nih.gov, with no costs incurred by the government for responses.
    Small business Education and Entrepreneurial Development (SEED) Support Services
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide support services for the Small business Education and Entrepreneurial Development (SEED) initiative. This procurement aims to enhance the navigation of the laboratory-to-market pipeline for biomedical innovators by offering targeted regulatory and commercialization support, as well as educational resources to improve outcomes for NIH-funded projects. The SEED office plays a crucial role in advancing discoveries into products that benefit patient health, aligning with NIH's strategic objectives to foster innovation in the life sciences. Interested firms must submit their capability statements to Donald Ledwig at donald.ledwig@nih.gov by January 24, 2025, at 3:00 PM, with no telephone inquiries accepted.
    Access to Outpatient Longitudinal Drug Utilization Data
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide access to outpatient longitudinal drug utilization data through a Sources Sought notice. The primary objective is to acquire existing, HIPAA-compliant data resources that will enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions, rather than developing new databases. This initiative is crucial for monitoring medication utilization trends, particularly in areas such as opioid surveillance, and aims to improve public health outcomes through rigorous analyses of drug safety data. Interested firms must submit their responses by January 23, 2025, including their business size status and DUNS number, and can direct inquiries to Telisha Wilson at telisha.wilson@fda.hhs.gov.
    Fiber Photometry Processors
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from small businesses regarding their capabilities to provide Fiber Photometry Processors, particularly the RZ5P model, which is essential for data acquisition and processing in the study of substance use disorders. The processors will be used to record neurotransmitter activity, such as dopamine, during behavioral experiments and substance administration, contributing to the understanding of substance use disorder mechanisms. Interested small businesses, including those classified as HUBZone, service-disabled veteran-owned, and woman-owned, are invited to submit a capability statement detailing their qualifications and relevant experience by January 29, 2025. For further inquiries, potential respondents can contact Joseph Kennedy at joseph.kennedy@nih.gov or Marlene Milgram at marlene.milgram@nih.gov.
    Biological Therapeutics Product Development Subject Matter Expert Consultants
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), is seeking proposals for consulting services from subject matter expert (SME) consultants to support the development of biological therapeutics. The objective of this procurement is to engage SMEs who can provide technical recommendations across various phases of drug discovery and development, including chemistry, regulatory affairs, and clinical trial design, particularly for novel therapeutics aimed at neurological disorders and rare genetic conditions. This initiative is crucial for advancing NIH drug discovery programs and ensuring that innovative therapeutic solutions progress efficiently to clinical evaluation. Interested vendors must submit their proposals by January 27, 2025, and can direct inquiries to Shayna Simpson at shayna.simpson@nih.gov or Kelly Dempsey at kelly.dempsey@nih.gov. The contract is expected to span one year with two optional extensions, and the anticipated performance period is from April 1, 2025, to March 30, 2026.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.